Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Digital Prenatal Education to Reduce Fear of Childbirth in Term Pregnancy (FEARLESS-BIRTH)

30 de julho de 2026 atualizado por: Sergio Mies Padilla

Impact of a Digital Prenatal Education Intervention on Fear of Childbirth in Term Pregnant Women: A Randomized Controlled Trial

Many pregnant women feel afraid of giving birth. This fear is common and can affect how a woman experiences labour, the type of birth she has, and how she feels afterwards.

Antenatal education helps women prepare for birth, but not everyone can attend the classes offered at health centres. Work schedules, family duties or travel distance often get in the way.

This study looks at whether an online education programme can help. The programme is a website that women can use at home, at any time, from a phone, tablet or computer. It explains how labour works, what pain relief and other options are available, how to prepare a birth plan, and how to manage difficult feelings. It also includes videos filmed in the hospital where the women will give birth, so the place feels familiar before they arrive.

Women taking part will be pregnant with one baby, will have a pregnancy considered low risk, and will be at least 37 weeks pregnant when they start. Half of the women will be given access to the website, chosen at random, like tossing a coin. The other half will receive the usual antenatal care offered by their midwife and doctor. All women continue with their normal pregnancy care.

Women will answer a questionnaire about their feelings towards birth when they join the study, and a second questionnaire in the first two weeks after their baby is born. The researchers will compare the answers of the two groups to see whether the website made a difference. Information about the birth will also be collected from the medical records.

The study will take place in Gran Canaria, Spain, and will include 176 women. It is run by midwives as part of a specialist training programme and has no commercial funding.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Background. Fear of childbirth affects approximately 14% of pregnant women worldwide and has been associated with higher rates of maternal request caesarean section, greater use of epidural analgesia, prolonged second stage of labour, poorer postpartum mental health and difficulties with breastfeeding initiation. Structured antenatal education reduces fear of childbirth, but attendance at face-to-face programmes is limited by scheduling conflicts, occupational demands and geographical distance. Digital health interventions may overcome these barriers, yet evidence on stand-alone web-based antenatal education targeting term pregnancies, assessed with validated instruments and compared against usual care in a randomised design, remains scarce, particularly in the Spanish health care context.

Design. Single-centre, two-arm, parallel-group randomised controlled trial with 1:1 allocation. The protocol was developed in accordance with the SPIRIT statement, and the intervention is described following the TIDieR checklist.

Setting. Antenatal care services within the catchment area of the Complejo Hospitalario Universitario Insular Materno Infantil (CHUIMI), a tertiary public hospital of the Canary Islands Health Service in Gran Canaria, Spain. Recruitment takes place at both primary care midwifery clinics and hospital obstetric outpatient clinics.

Participants and procedures. Women are approached prospectively at any point during pregnancy and provide initial informed consent. Definitive eligibility is reassessed at 37+0 weeks of gestation, when consent is ratified, the baseline questionnaire is completed and randomisation takes place. This two-stage consent procedure protects participant autonomy and ensures that allocation occurs only among women who still meet low-risk criteria at term.

Randomisation and blinding. The allocation sequence is computer-generated centrally using simple randomisation (Epidat 4.2) and concealed in sequentially numbered, opaque, sealed envelopes opened in strict numerical order. Blinding of participants is not feasible given the nature of the intervention. Third-party blinding is applied: the clinicians attending labour are unaware of group allocation, so that intrapartum care is identical for all participants. Statistical analysis is performed by an external analyst working with a pseudonymised database in which the allocation variable is coded.

Intervention. Participants allocated to the experimental arm receive personal credentials for an interactive antenatal education website, activated at 37 weeks and accessible until hospital admission for birth. Content is delivered asynchronously through multimedia modules covering fear of childbirth, physiology of labour, pain management options, obstetric interventions, emotional coping strategies, guidance for the birth companion, immediate newborn care, and a virtual tour of the labour ward facilities. Materials are evidence-based and adapted to local clinical protocols. Server metrics automatically record logins, session duration and modules accessed, allowing objective assessment of adherence and intervention fidelity. Participants allocated to the control arm receive standard antenatal care only, including the option of attending conventional face-to-face antenatal classes, and are not given access to the platform.

Assessments. Fear of childbirth is measured with the Spanish version of the Wijma Delivery Expectancy/Experience Questionnaire: the expectancy version (W-DEQ-A-Sp, 31 items, range 0-155) at baseline (37 weeks, T0) and the experience version (W-DEQ-B-Sp, 33 items, range 0-165) during the first 15 days postpartum (T1). Obstetric and neonatal outcomes are extracted retrospectively from the electronic health record after birth.

Sample size. Assuming a population standard deviation of 15 points, a minimum clinically relevant difference of 9 points on the W-DEQ, alpha of 0.05 (two-sided), power of 80% and 1:1 allocation, 44 participants per arm are required. Given the interval between early recruitment and activation of the intervention at term, and the documented attrition in previous trials in this population and setting, a 50% loss to follow-up is anticipated. The final target is therefore 88 participants per arm, 176 in total.

Statistical analysis. Analyses are conducted in SPSS with a significance level of p < 0.05 and 95% confidence intervals. Normality is assessed using Kolmogorov-Smirnov or Shapiro-Wilk tests. Between-group comparisons use independent-samples t tests or Mann-Whitney U tests; within-group changes use paired t tests or Wilcoxon signed-rank tests; categorical variables use chi-square or Fisher's exact tests. The primary analysis follows the intention-to-treat principle with multiple imputation for missing postpartum data. A per-protocol sensitivity analysis includes only participants in the experimental arm meeting a minimum threshold of platform adherence, in order to explore a possible dose-response relationship.

Ethics. The protocol received a favourable opinion from the CEI/CEIm of Las Palmas (reference 2026-249-1). The intervention is classified as minimal risk. Data are processed in accordance with Regulation (EU) 2016/679 and Spanish Organic Law 3/2018, using pseudonymisation with a separately stored linkage document.

Tipo de estudo

Intervencional

Inscrição (Estimado)

176

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • LAS Palmas
      • Las Palmas de Gran Canaria, LAS Palmas, Espanha, 35000
        • Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria
        • Contato:
        • Contato:
        • Subinvestigador:
          • Lucía Sanzo López, RM
        • Subinvestigador:
          • Marlene Fernández Padrón, RM

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Aged 18 years or older
  • Nulliparous or multiparous
  • Singleton pregnancy
  • Pregnancy classified as low obstetric risk according to current local protocols
  • Antenatal care provided at primary or specialised care centres within the catchment area of the Complejo Hospitalario Universitario Insular Materno Infantil (CHUIMI)
  • Access to an internet-connected electronic device (smartphone, tablet or computer) allowing use of the web-based educational platform
  • Able to understand, read and write in Spanish
  • Written informed consent
  • Gestational age between 37+0 and 42+0 weeks at the time of definitive eligibility confirmation, baseline questionnaire completion and randomisation

Exclusion Criteria:

  • Estimated date of delivery, calculated by first-trimester ultrasound, later than 31 January 2027
  • Risk of preterm birth or medical indication for early termination of pregnancy at the time of recruitment
  • Elective caesarean section scheduled at the time of recruitment
  • Known major structural fetal anomaly requiring specialised obstetric or neonatal management
  • Previous or current diagnosis of an anxiety disorder, depression or other relevant psychopathology that, in the judgement of the recruiting clinician, could interfere with study participation
  • Concurrent participation in another structured intervention study specifically targeting fear of childbirth
  • Planned relocation outside the CHUIMI catchment area before the estimated date of delivery, precluding postpartum data collection

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Web-based prenatal education
Participants receive personal credentials for an interactive web-based prenatal education platform, activated at 37+0 weeks of gestation and accessible until hospital admission for birth, in addition to standard antenatal care.
Asynchronous, self-paced digital education programme delivered through a password-protected website accessible from any internet-connected device. Content is organised in multimedia modules covering fear of childbirth, physiology of labour, pain management options, obstetric interventions, emotional coping strategies, guidance for the birth companion, immediate newborn care, and a virtual tour of the labour ward. Materials are evidence-based and adapted to local clinical protocols. Access is activated at 37+0 weeks and remains available until admission for birth. Server metrics record logins, session duration and modules accessed.
Sem intervenção: Usual care
Participants receive standard antenatal care according to the protocols of the Canary Islands Health Service for low-risk pregnancy, including scheduled midwifery and obstetric visits and the option of attending conventional face-to-face antenatal classes. No access to the study platform is provided.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Fear of childbirth (Wijma Delivery Expectancy/Experience Questionnaire, version B)
Prazo: Between day 1 and day 15 postpartum
Fear of childbirth related to the birth experience, measured with the Spanish version of the Wijma Delivery Expectancy/Experience Questionnaire, experience version (W-DEQ-B-Sp). The instrument is self-administered and comprises 33 items rated on a 6-point Likert scale (0 = not at all to 5 = extremely). Total scores range from 0 to 165, with higher scores indicating greater fear of childbirth. Items 2, 3, 6, 7, 8, 11, 12, 15, 19, 20, 24, 25, 27 and 31 are reverse-scored. Cronbach's alpha in the Spanish validation study was 0.93. Scores are compared between arms, adjusted for baseline W-DEQ-A-Sp score.
Between day 1 and day 15 postpartum

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Baseline fear of childbirth (W-DEQ-A-Sp)
Prazo: At 37+0 to 42+0 weeks of gestation, immediately before randomisation
Antenatal fear of childbirth measured with the Spanish expectancy version of the Wijma questionnaire (W-DEQ-A-Sp), 31 items rated 0-5, total score range 0-155, higher scores indicating greater fear. Cronbach's alpha 0.91. Collected prior to randomisation to characterise baseline levels and to confirm comparability between arms.
At 37+0 to 42+0 weeks of gestation, immediately before randomisation
Onset of labour
Prazo: At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Categorised as spontaneous or induced, extracted from the electronic health record.
At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Use of synthetic oxytocin during labour
Prazo: At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Intravenous administration of exogenous oxytocin to induce or augment uterine contractions (yes/no), extracted from the electronic health record.
At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Use of epidural analgesia
Prazo: At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Effective administration of neuraxial analgesia during labour (yes/no), extracted from the electronic health record.
At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Duration of labour
Prazo: At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Time in hours from admission to the labour ward in active phase to delivery of the placenta, extracted from the electronic health record.
At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Mode of birth
Prazo: At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Categorised as spontaneous vaginal birth, instrumental vaginal birth or caesarean section, extracted from the electronic health record.
At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Apgar score
Prazo: At 1 and 5 minutes after birth
Neonatal vitality and physiological adaptation scored from 0 to 10 at 1 and 5 minutes of life, extracted from the electronic health record.
At 1 and 5 minutes after birth
Gestational age at birth
Prazo: At birth, assessed through study completion (up to approximately 5 weeks after randomisation)
Duration of pregnancy in completed weeks and days at the time of birth, calculated preferentially from first-trimester dating ultrasound.
At birth, assessed through study completion (up to approximately 5 weeks after randomisation)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Adherence to the intervention (experimental arm only)
Prazo: From randomisation at 37+0 weeks until hospital admission for birth (up to approximately 5 weeks)
Level of exposure to the intervention, recorded automatically by the platform server: total number of logins, session duration and number of modules completed per participant.
From randomisation at 37+0 weeks until hospital admission for birth (up to approximately 5 weeks)
Attendance at face-to-face antenatal education
Prazo: Between day 1 and day 15 postpartum
Attendance at the conventional antenatal education programme delivered by primary care midwives, recorded as yes/no and, where applicable, as the number of sessions attended. Collected by self-report at T1 and verified against the primary care electronic health record.
Between day 1 and day 15 postpartum
Sources of childbirth information consulted
Prazo: At 37+0 to 42+0 weeks of gestation and between day 1 and day 15 postpartum
Self-reported use of digital and non-digital sources of information about labour and birth during the third trimester, collected in both arms to assess potential contamination of the control group.
At 37+0 to 42+0 weeks of gestation and between day 1 and day 15 postpartum

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Sabela Jiménez López RM, Complejo Hospitalario Universitario Materno Infantil de Canarias

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2026

Conclusão do estudo (Estimado)

30 de janeiro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de julho de 2026

Primeira postagem (Real)

4 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever